AR069435A1 - Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa - Google Patents
Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasaInfo
- Publication number
- AR069435A1 AR069435A1 ARP080105161A ARP080105161A AR069435A1 AR 069435 A1 AR069435 A1 AR 069435A1 AR P080105161 A ARP080105161 A AR P080105161A AR P080105161 A ARP080105161 A AR P080105161A AR 069435 A1 AR069435 A1 AR 069435A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- halogen
- haloalkyl
- alkoxy
- alkyl
- Prior art date
Links
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 4
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 abstract 1
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- -1 carboxy ester Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Compuestos de la formula (1) en la que R1 es como en formulas (2) o (3), X es S, N-R7 u O; R2 y R3 se eligen en cada caso con independencia entre hidrogeno, alquilo, alcoxi, cicloalquilo, haloalquilo, haloalcoxi, arilo, ariloxi, alcoxialquilo, alcoxicarbonilo, alcoxialcoxi, hidroxialcoxi, heterociclilo, heterocicloalquilo, halogeno, aralquilo, hidroxilo, -S-R8, -O-R8, -N(R8)2, -R10-S-R8, -R10-O-R8, -R10-N(R8)2, nitro, ciano y -C(O)R7, -R8-C(O)R7; o R2 y R3 junto con los átomos de carbono a los que están unidos forman un anillo insaturado de 5 o 6 eslabones, que puede tener 1 o 2 heteroátomos elegidos entre N, O y S, dicho anillo está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre R9, -O-R9, -O-CO-R9, -NR9-CO-R9, -S-R9, -SO-R9, -SO2-R9, -CO2-R9, -CON(R9)2, -R10-O-R9, -R10-O-COR9, -R10-NR9-COR9, -R10-S-R9, -R10-SO-R9, -R10-SO2-R9, -R10-CO2-R9, -R10-CON(R9)2 y N(R9)2; con la condicion de que R2 no sea hidrogeno y r3 no sea halogeno, cuando X es S y R4 y r5 no forman un anillo; R4 y R5 se eligen con independencia entre hidrogeno, alquilo, alcoxi, cicloalquilo, haloalquilo, haloalcoxi, hidroxialquilo, arilo, ariloxi, alcoxialquilo, alcoxicarbonilo, alcoxialcoxi, hidroxialcoxi, heterociclilo, heterocicloalquilo, halogeno; aralquilo, hidroxilo, amino, nitro, ciano o -C(O)R7, -R8-C(O)R7 y R10-O-C(O)R7; o R4 y R5 junto con los átomos de carbono a los que están unidos forman un anillo insaturado o saturado de 5 o 6 eslabones que puede tener 1 o 2 heteroátomos elegidos entre N, O y S, dicho anillo está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre R9, -O-R9, -O-CO-R9, -NR9-CO-R9, -S-R9, -SO-R9, -SO2-R9, -CO2-R9, -CON(R9)2, -R10-O-R9, -R10-O-COR9, -R10-NR9-COR9, -R10-S-R9, -R10-SO-R9, -R10-SO2-R9; -R10-CO2-R9; -R10-CON(R9)2, N(R9), ciano, nitro y halogeno; R6 es hidrogeno, alquilo, alcoxi, halogeno, haloalquilo, haloalcoxi, alcoxialquilo o alcoxialcoxi; R7 es hidrogeno, alquilo, alcoxi, haloalcoxi, alcoxialquilo, alcoxialcoxi, hidroxialcoxi, hidroxialquilo, cicloalquilo, heterocicloalquilo, aralquilo, hidroxilo o haloalquilo; R8 se elige en cada caso con independencia entre hidrogeno alquilo, cicloalquilo, heterocicloalquilo, aralquilo o haloalquilo; R9 se elige en cada caso con independencia entre hidrogeno y un resto orgánico saturado y/o insaturado, acíclico y/o cíclico que puede tener hasta 20 átomos de carbono y hasta 5 heteroátomos elegidos entre N, S y/u O, que puede estar sustituido por halogeno, hidroxi, alcoxi, -C(O)R7, -R8-C(O)R7, R10-O-C(O)R7, carboxi-éster o carboxiamida; R10 es alquileno, arileno, aralquileno, alcarileno; y las sales y ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122019 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069435A1 true AR069435A1 (es) | 2010-01-20 |
Family
ID=40430064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105161A AR069435A1 (es) | 2007-11-30 | 2008-11-27 | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7973051B2 (es) |
| EP (1) | EP2227468A1 (es) |
| JP (1) | JP2011504897A (es) |
| KR (1) | KR20100080853A (es) |
| CN (1) | CN101878211A (es) |
| AR (1) | AR069435A1 (es) |
| AU (1) | AU2008328955B2 (es) |
| BR (1) | BRPI0820622A2 (es) |
| CA (1) | CA2706574A1 (es) |
| IL (1) | IL205751A0 (es) |
| MX (1) | MX2010005824A (es) |
| PE (1) | PE20091425A1 (es) |
| TW (1) | TW200922563A (es) |
| WO (1) | WO2009068467A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101990337B (zh) * | 2009-08-03 | 2014-03-26 | 联咏科技股份有限公司 | 可动态维持定电流驱动的光源驱动装置及其相关方法 |
| DK3252057T3 (da) | 2009-12-04 | 2024-06-17 | Sunovion Pharmaceuticals Inc | Multicykliske forbindelser og fremgangsmåder til anvendelse deraf |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| CN116283877A (zh) | 2016-07-29 | 2023-06-23 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
| AU2017301767A1 (en) | 2016-07-29 | 2019-02-14 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| CN110678205B (zh) | 2017-02-16 | 2023-05-23 | 桑诺维恩药品公司 | 治疗精神分裂症的方法 |
| KR20200036008A (ko) | 2017-08-02 | 2020-04-06 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로만 화합물 및 이의 용도 |
| JP7453148B2 (ja) | 2018-02-16 | 2024-03-19 | サノビオン ファーマシューティカルズ インク | 塩、結晶形態、およびその製造方法 |
| WO2020002090A1 (de) | 2018-06-25 | 2020-01-02 | Bayer Aktiengesellschaft | Substituierte thiazolylpyrrolone sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| US20230011652A1 (en) * | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| MX2022012833A (es) | 2020-04-14 | 2022-11-07 | Sunovion Pharmaceuticals Inc | (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933355A (en) | 1988-04-14 | 1990-06-12 | Sankyo Company Limited | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications |
| PL335052A1 (en) * | 1997-01-29 | 2000-03-27 | Pfizer | Derivatives of sulphonylurea and their application in regulating activity of interleukin-1 |
| DK1257550T3 (da) | 2000-02-04 | 2006-03-27 | Portola Pharm Inc | Blodplade-ADP-receptor-inhibitor |
| WO2003039451A2 (en) | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
| CN1946703A (zh) * | 2004-04-20 | 2007-04-11 | 特兰斯泰克制药公司 | 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂 |
| DK200600313A (da) | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
| EP2032548A1 (en) * | 2006-06-01 | 2009-03-11 | F.Hoffmann-La Roche Ag | Thiazole derivatives |
-
2008
- 2008-11-10 US US12/267,661 patent/US7973051B2/en not_active Expired - Fee Related
- 2008-11-20 MX MX2010005824A patent/MX2010005824A/es active IP Right Grant
- 2008-11-20 CN CN2008801184683A patent/CN101878211A/zh active Pending
- 2008-11-20 JP JP2010535336A patent/JP2011504897A/ja active Pending
- 2008-11-20 WO PCT/EP2008/065910 patent/WO2009068467A1/en not_active Ceased
- 2008-11-20 BR BRPI0820622-8A patent/BRPI0820622A2/pt not_active IP Right Cessation
- 2008-11-20 KR KR1020107011826A patent/KR20100080853A/ko not_active Abandoned
- 2008-11-20 AU AU2008328955A patent/AU2008328955B2/en not_active Expired - Fee Related
- 2008-11-20 EP EP08853191A patent/EP2227468A1/en not_active Withdrawn
- 2008-11-20 CA CA2706574A patent/CA2706574A1/en not_active Abandoned
- 2008-11-25 PE PE2008001973A patent/PE20091425A1/es not_active Application Discontinuation
- 2008-11-27 AR ARP080105161A patent/AR069435A1/es unknown
- 2008-11-27 TW TW097146042A patent/TW200922563A/zh unknown
-
2010
- 2010-05-13 IL IL205751A patent/IL205751A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200922563A (en) | 2009-06-01 |
| CN101878211A (zh) | 2010-11-03 |
| PE20091425A1 (es) | 2009-09-23 |
| WO2009068467A1 (en) | 2009-06-04 |
| MX2010005824A (es) | 2010-06-11 |
| KR20100080853A (ko) | 2010-07-12 |
| CA2706574A1 (en) | 2009-06-04 |
| EP2227468A1 (en) | 2010-09-15 |
| AU2008328955A1 (en) | 2009-06-04 |
| US20090143448A1 (en) | 2009-06-04 |
| BRPI0820622A2 (pt) | 2015-06-16 |
| IL205751A0 (en) | 2010-11-30 |
| JP2011504897A (ja) | 2011-02-17 |
| AU2008328955B2 (en) | 2012-12-13 |
| US7973051B2 (en) | 2011-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
| AR069436A1 (es) | Compuestos de piridina | |
| AR060768A1 (es) | Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos. | |
| AR054081A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| ES2630079T3 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR072428A1 (es) | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. | |
| AR077043A2 (es) | Pirimidinonas biciclicas y sus usos | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| AR079250A1 (es) | Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis. | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR078722A1 (es) | Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| AR046170A1 (es) | Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |